A Study of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Non Small Cell Lung Cancer Stage IIIB
- Interventions
- Drug: Standard of Care
- First Posted Date
- 2018-03-21
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- BioMarck Pharmaceuticals, Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT03472053
- Locations
- ๐ฎ๐ณ
Vardhman Mahavir Medical College & Hospital, New Delhi, Delhi, India
๐ฎ๐ณDeenanath Mangeshkar Hospital & Research Center, Pune, Maharashtra, India
๐ฎ๐ณAadhar Health Institute, Hisar, Hariyana, India
Evaluation of Safety & Efficacy of BIO-11006 Inhalation Solution in Patients With ARDS
Phase 2
Completed
- Conditions
- Respiratory Distress Syndrome, Adult
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-06-28
- Last Posted Date
- 2020-06-25
- Lead Sponsor
- BioMarck Pharmaceuticals, Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT03202394
- Locations
- ๐บ๐ธ
University of Chicago Medicine, Chicago, Illinois, United States
๐บ๐ธUniversity of Pennsylvania, Philadelphia, Pennsylvania, United States
๐บ๐ธVanderbilt University, Div of Allergy, Pulmonary, Critical Care, Nashville, Tennessee, United States
Effectiveness and Safety of BIO-11006 Inhalation Solution to Treat the Overproduction of Mucus and Inflammation in COPD
Phase 2
Completed
- Conditions
- COPDChronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2011-02-10
- Lead Sponsor
- BioMarck Pharmaceuticals, Ltd.
- Target Recruit Count
- 172
- Registration Number
- NCT00648245
- Locations
- ๐บ๐ธ
VA Sierra Nevada Health Care System, Reno, Nevada, United States
๐บ๐ธPulmonary Associates, Glendale, Arizona, United States
๐บ๐ธGreater Los Angeles Healthcare System, Los Angeles, California, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath